What to say and how to say it

Effective communication for cardiovascular disease prevention

Ann Marie Navar, Neil J. Stone, Seth Martin

Research output: Contribution to journalReview article

Abstract

Purpose of review Current guidelines for cholesterol treatment emphasize the importance of engaging patients in a risk-benefit discussion prior to initiating statin therapy. Recent findings Although current risk prediction algorithms are well defined, there is less data on how to communicate with patients about cardiovascular disease risk, benefits of treatment, and possible adverse effects. Summary We propose a four-part model for effective shared decision-making: 1) Assessing patient priorities, perceived risk, and prior experience with cardiovascular risk reduction; 2) Arriving at a recommendation for therapy based on the patient's risk of disease, guideline recommendations, new clinical trial data, and patient preferences; 3) Communicating this recommendation along with risks, benefits, and alternatives to therapy following best practices for discussing numeric risk; and 4) Arriving at a shared decision with the patient with ongoing reassessment as risk factors and patient priorities change.

Original languageEnglish (US)
Pages (from-to)537-544
Number of pages8
JournalCurrent Opinion in Cardiology
Volume31
Issue number5
DOIs
StatePublished - Sep 1 2016

Fingerprint

Cardiovascular Diseases
Communication
Guidelines
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Patient Preference
Risk Reduction Behavior
Therapeutics
Complementary Therapies
Practice Guidelines
Decision Making
Cholesterol
Clinical Trials

Keywords

  • prevention
  • risk communication
  • shared decision-making

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

What to say and how to say it : Effective communication for cardiovascular disease prevention. / Navar, Ann Marie; Stone, Neil J.; Martin, Seth.

In: Current Opinion in Cardiology, Vol. 31, No. 5, 01.09.2016, p. 537-544.

Research output: Contribution to journalReview article

@article{d8f23c9a485b47d697b55ca88f3aa527,
title = "What to say and how to say it: Effective communication for cardiovascular disease prevention",
abstract = "Purpose of review Current guidelines for cholesterol treatment emphasize the importance of engaging patients in a risk-benefit discussion prior to initiating statin therapy. Recent findings Although current risk prediction algorithms are well defined, there is less data on how to communicate with patients about cardiovascular disease risk, benefits of treatment, and possible adverse effects. Summary We propose a four-part model for effective shared decision-making: 1) Assessing patient priorities, perceived risk, and prior experience with cardiovascular risk reduction; 2) Arriving at a recommendation for therapy based on the patient's risk of disease, guideline recommendations, new clinical trial data, and patient preferences; 3) Communicating this recommendation along with risks, benefits, and alternatives to therapy following best practices for discussing numeric risk; and 4) Arriving at a shared decision with the patient with ongoing reassessment as risk factors and patient priorities change.",
keywords = "prevention, risk communication, shared decision-making",
author = "Navar, {Ann Marie} and Stone, {Neil J.} and Seth Martin",
year = "2016",
month = "9",
day = "1",
doi = "10.1097/HCO.0000000000000322",
language = "English (US)",
volume = "31",
pages = "537--544",
journal = "Current Opinion in Cardiology",
issn = "0268-4705",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - What to say and how to say it

T2 - Effective communication for cardiovascular disease prevention

AU - Navar, Ann Marie

AU - Stone, Neil J.

AU - Martin, Seth

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Purpose of review Current guidelines for cholesterol treatment emphasize the importance of engaging patients in a risk-benefit discussion prior to initiating statin therapy. Recent findings Although current risk prediction algorithms are well defined, there is less data on how to communicate with patients about cardiovascular disease risk, benefits of treatment, and possible adverse effects. Summary We propose a four-part model for effective shared decision-making: 1) Assessing patient priorities, perceived risk, and prior experience with cardiovascular risk reduction; 2) Arriving at a recommendation for therapy based on the patient's risk of disease, guideline recommendations, new clinical trial data, and patient preferences; 3) Communicating this recommendation along with risks, benefits, and alternatives to therapy following best practices for discussing numeric risk; and 4) Arriving at a shared decision with the patient with ongoing reassessment as risk factors and patient priorities change.

AB - Purpose of review Current guidelines for cholesterol treatment emphasize the importance of engaging patients in a risk-benefit discussion prior to initiating statin therapy. Recent findings Although current risk prediction algorithms are well defined, there is less data on how to communicate with patients about cardiovascular disease risk, benefits of treatment, and possible adverse effects. Summary We propose a four-part model for effective shared decision-making: 1) Assessing patient priorities, perceived risk, and prior experience with cardiovascular risk reduction; 2) Arriving at a recommendation for therapy based on the patient's risk of disease, guideline recommendations, new clinical trial data, and patient preferences; 3) Communicating this recommendation along with risks, benefits, and alternatives to therapy following best practices for discussing numeric risk; and 4) Arriving at a shared decision with the patient with ongoing reassessment as risk factors and patient priorities change.

KW - prevention

KW - risk communication

KW - shared decision-making

UR - http://www.scopus.com/inward/record.url?scp=84978681139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978681139&partnerID=8YFLogxK

U2 - 10.1097/HCO.0000000000000322

DO - 10.1097/HCO.0000000000000322

M3 - Review article

VL - 31

SP - 537

EP - 544

JO - Current Opinion in Cardiology

JF - Current Opinion in Cardiology

SN - 0268-4705

IS - 5

ER -